When to Order Imaging for Staging and Follow-up of Vulvar Cancer: ACR Appropriateness Decoded

A patient’s biopsy confirms vulvar squamous cell carcinoma. The next critical step is accurate staging to guide treatment, from local excision to radical vulvectomy with lymph node dissection and possible chemoradiation. Choosing the right initial imaging—or deciding that no imaging is needed—is a key decision point. Over-imaging early-stage disease can lead to unnecessary costs and patient anxiety, while under-imaging advanced disease can result in inadequate treatment planning. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria to help you select the right study for the right clinical scenario.

What Does ACR Staging and Follow-up of Vulvar Cancer Cover?

This ACR guideline provides evidence-based recommendations for imaging in two primary contexts: the initial, pretreatment staging of pathologically confirmed vulvar cancer and the post-treatment evaluation for clinically suspected recurrence. The criteria are stratified based on the clinical assessment of the primary tumor size and local invasion, which directly correspond to the FIGO (International Federation of Gynecology and Obstetrics) staging system. These recommendations are designed to evaluate the local extent of the primary tumor, assess for nodal metastases (inguinal and pelvic), and detect distant metastatic disease.

This document does not cover the initial diagnosis of a suspicious vulvar lesion, for which biopsy remains the gold standard. It also does not address routine, asymptomatic surveillance imaging after treatment; rather, it focuses on situations where there is a clinical concern for recurrent disease (e.g., new symptoms or palpable findings).

What Imaging Should I Order for Staging and Follow-up of Vulvar Cancer? Recommendations by Clinical Scenario

The ACR’s recommendations for imaging in vulvar cancer are highly dependent on the initial clinical stage of the disease. For very early-stage cancer, imaging is generally not required, while for more advanced or recurrent disease, cross-sectional imaging becomes essential.

For an initial staging of pretreatment vulvar cancer where the primary tumor is ≤ 2 cm, confined to the vulva or perineum, and with ≤ 1 mm stromal invasion (FIGO Stage IA), the ACR rates nearly all imaging modalities as Usually Not Appropriate. This includes MRI, CT, PET/CT, and ultrasound. At this early stage, the risk of nodal or distant metastatic disease is extremely low, and clinical assessment and surgical staging are sufficient. Imaging is unlikely to provide additional information that would alter management.

When the tumor is larger or more invasive—specifically, for an initial staging where the primary tumor is ≤ 4 cm with > 1 mm stromal invasion, or with minimal involvement of the distal urethra, vagina, or anus (FIGO Stage IB-II)—the recommendations change. In this scenario, MRI pelvis without and with IV contrast is rated as Usually Appropriate. MRI provides excellent soft-tissue resolution to define the extent of the primary tumor and its relationship to adjacent structures like the urethra, bladder, and rectum, which is critical for surgical planning. Lymphoscintigraphy for sentinel lymph node mapping may also be appropriate.

For locally advanced disease, defined as an initial staging where the primary tumor is > 4 cm or has more than minimal involvement of the proximal urethra, vagina, or anus (FIGO Stage III-IV), more extensive imaging is warranted. MRI pelvis without and with IV contrast remains Usually Appropriate for local disease assessment. In addition, CT chest abdomen pelvis with IV contrast and FDG-PET/CT skull base to mid-thigh are also rated as Usually Appropriate. These modalities are used to evaluate for pelvic and inguinal lymphadenopathy as well as distant metastatic disease, which is more common in advanced primary tumors.

Finally, for a post-treatment assessment of clinically suspected recurrence of known vulvar cancer, the imaging approach mirrors that of advanced primary disease. MRI pelvis without and with IV contrast is Usually Appropriate to evaluate local recurrence, while CT chest abdomen pelvis with IV contrast and FDG-PET/CT skull base to mid-thigh are also Usually Appropriate to assess the full extent of disease, including nodal and distant sites. The choice between these modalities often depends on the location of suspected recurrence and institutional preference.

ACR Imaging Recommendations Table

Adult vs. Pediatric Staging and Follow-up of Vulvar Cancer Imaging: Radiation Dose Tradeoffs

Vulvar cancer is exceedingly rare in the pediatric population. However, the ACR provides pediatric-specific relative radiation level (RRL) estimates for imaging studies involving ionizing radiation. The fundamental principles of imaging selection remain the same, but the emphasis on radiation safety is heightened. For children and adolescents, adherence to the As Low As Reasonably Achievable (ALARA) principle is critical to minimize cumulative lifetime radiation exposure. When cross-sectional imaging is necessary for advanced disease, MRI is often preferred over CT for pelvic evaluation due to its lack of ionizing radiation. If CT is required to assess for distant metastatic disease, protocols should be specifically tailored to the pediatric patient to reduce the radiation dose. The RRL tables show that pediatric CT scans are often in a different dose category than their adult counterparts, reflecting these dose-reduction efforts.

Imaging Protocol Details for Staging and Follow-up of Vulvar Cancer

Once you’ve decided on the right study, the specific imaging protocol is crucial for obtaining diagnostic-quality images. Our protocol guides cover key details on technique, contrast administration, and interpretation principles for many of the studies recommended in these ACR criteria.

• US Carotid Doppler
• CT Abdomen/Pelvis Without Contrast (Renal Stone)

Tools to Help You Order the Right Study

Navigating imaging guidelines can be complex. GigHz offers a suite of tools designed to support clinical decision-making and streamline the imaging workflow for physicians and trainees.

For scenarios beyond vulvar cancer, the ACR Appropriateness Criteria Lookup tool provides direct access to the full library of ACR guidelines, helping you find evidence-based recommendations for hundreds of clinical conditions.

To ensure studies are performed correctly, the Imaging Protocol Library offers detailed, step-by-step protocols for a wide range of CT, MRI, and ultrasound examinations, ensuring you and your technologists are aligned on technique.

When discussing the risks and benefits of imaging with patients, especially concerning studies that involve radiation, the Radiation Dose Calculator can help estimate and track cumulative radiation exposure, facilitating informed patient conversations.

Frequently Asked Questions

Why is imaging ‘Usually Not Appropriate’ for Stage IA vulvar cancer?

For Stage IA vulvar cancer (tumors ≤ 2 cm with ≤ 1 mm stromal invasion), the risk of lymph node metastasis is less than 1%. Given this very low risk, the potential harms of imaging—including cost, radiation exposure (for CT/PET), and the possibility of false positives leading to more invasive testing—outweigh the potential benefits. Management is guided by surgical excision and pathologic analysis of the specimen.

When should I choose PET/CT over CT for staging advanced vulvar cancer?

Both CT of the chest, abdomen, and pelvis with IV contrast and FDG-PET/CT are rated ‘Usually Appropriate’ for staging locally advanced (Stage III-IV) disease. PET/CT may be more sensitive for detecting nodal and distant metastases and can be particularly useful for treatment planning, especially if radiation therapy is being considered. However, it involves higher radiation exposure and cost. The choice often depends on institutional preference and the specific clinical question being asked.

Is an MRI of the pelvis always necessary if a CT of the abdomen and pelvis is being done?

For locally advanced disease, MRI of the pelvis is superior to CT for evaluating the local extent of the tumor and its invasion into adjacent structures like the urethra, bladder, vagina, and rectum. CT is better for assessing distant disease in the abdomen and chest. In many cases of advanced cancer, both studies may be complementary and necessary for comprehensive staging: MRI for the ‘T’ stage (local tumor) and CT for the ‘M’ stage (distant metastases).

What is the role of ultrasound in vulvar cancer staging?

While ultrasound of the groin with fine-needle aspiration may be used to evaluate suspicious inguinal lymph nodes, the ACR rates it as ‘May be appropriate’ or ‘Usually not appropriate’ for primary staging, depending on the scenario. It is not the primary modality for assessing the local tumor or for comprehensive nodal staging. Cross-sectional imaging with MRI, CT, or PET/CT is preferred for a complete evaluation.

For suspected recurrence, does it matter where the recurrence is suspected?

Yes. If recurrence is suspected locally in the vulva or pelvis based on clinical exam, an MRI of the pelvis without and with contrast is the most appropriate initial study to characterize the abnormality. If there is concern for more widespread disease (e.g., new systemic symptoms, suspicious nodes outside the pelvis), then a CT of the chest, abdomen, and pelvis or a PET/CT would be more appropriate to assess the full extent of recurrence.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026